PATENT CLAIM ANALYSIS

Application Number: 16017520
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-12
Patent Classification: ["548", "400000"]

Abstract:
The present invention provides an erythropoietin expression-enhancing agent that can cancel the suppression of erythropoietin production or promote erythropoietin production, and a therapeutic or preventive drug for anemia, a liver function-improving agent, an ischemic injury-improving agent, a renal protective agent, and an insulin secretagogue comprising the erythropoietin expression-enhancing agent. The erythropoietin expression-enhancing agent of the present invention comprises one or more compounds selected from the group consisting of compounds represented by the following general formulas (I), (II), and (III) and pharmaceutically acceptable salts thereof when R 3  is OH.

Claim (Index 13):
The compound according to  claim 12 , which is represented by the following formula (III-1):\n Formula (III-1): or\n a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 94.0
- Lexical Diversity: 1.67742
- Patent Class: 548.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14646640', '12086792', '14156314', '15322271', '14434725']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7321230494753329
- 35 USC 102 Novelty (BERT): 0.5651840506586525
- Combined Prediction Score: 0.7154291495936649
- Mean Citation Score: 261.279832
- Max Citation Score: 459.8603
- Similarity Product: 362.64910702166566

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test